In conclusion, we developed rVSV-SARS-CoV-2-msp-SF-Gtc to be a dual rVSV serotype vaccine carrying a modified full-length SARS-CoV-2 S protein to induce robust neutralizing antibodies and cell-mediated immune responses towards wild-type SARS-CoV-2 as an effective vaccine candidate in the ongoing fight against the COVID-19 pandemic. The gene discussed is PROS1; the disease is COVID-19.